600080.SHG Ginwa Enterprise Group Inc
- Market cap
- CNY 1.49B
- P/E
- -
- P/B
- 0.94x
- ROE
- -3.0%
- Dividend yield
- 0.90%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600080.SHG undervalued?
Graham numberThe Graham number of Ginwa Enterprise Group Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ginwa Enterprise Group Inc fundamental analysis
No fundamental analysis for Ginwa Enterprise Group Inc yet.
Ginwa Enterprise Group Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ginwa Enterprise Group Inc
Ginwa Enterprise (Group) Inc. researches, develops, produces, markets, and sells traditional Chinese medicines, biological drugs, and chemical drugs primarily in China. The company offers a range of orthopaedics, immunity, children, and general medicines in various dosage forms, including tablets, capsules, powders, mixtures, oral solutions, syrups, and external solutions. It is also involved in the pharmaceutical logistics activities. The company was founded in 1996 and is …
Full company profileGinwa Enterprise Group Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ginwa Enterprise Group Inc annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 667M | 757M | 745M | 755M | 668M | 534M | 579M | 565M | 585M | 544M | 493M |
| Gross Profit | 420M | 479M | 507M | 537M | 472M | 400M | 441M | 432M | 458M | 419M | 357M |
| Operating Income | 38.4M | 40.2M | 43.1M | 42.4M | 43.5M | 43.8M | 17.1M | -32.9M | 49.0M | 5.32M | 4.09M |
| EBITDA | 70.3M | 96.9M | 76.5M | 70.2M | 77.3M | 6.07M | 75.8M | -3.92M | 61.0M | 42.7M | -57.0M |
| Net Income | 27.3M | 53.5M | 38.3M | 25.9M | 37.7M | -18.2M | 33.5M | -42.9M | 74.6M | 15.6M | -47.4M |
| EPS | 0.09 | 0.15 | 0.11 | 0.07 | 0.11 | -0.05 | 0.09 | -0.11 | 0.21 | 0.04 | -0.13 |
| Balance Sheet | |||||||||||
| Total Assets | 1.44B | 1.42B | 1.97B | 1.98B | 1.96B | 1.87B | 1.97B | 2.11B | 1.97B | 1.93B | 1.94B |
| Total Liabilities | 370M | 301M | 203M | 264M | 237M | 214M | 291M | 470M | 413M | 370M | 384M |
| Shareholders' Equity | 1.07B | 1.12B | 1.77B | 1.71B | 1.72B | 1.66B | 1.68B | 1.64B | 1.56B | 1.56B | 1.56B |
| Cash & Short-term Investments | 68.9M | 46.8M | 359M | 388M | 694M | 651M | 580M | 677M | 373M | 311M | 156M |
| Total Debt | 150M | 150M | 50.0M | 50.0M | 50.1M | - | 15.8M | 5.43M | 43.5M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 41.7M | 42.9M | 29.2M | 111M | 46.6M | 30.6M | 52.6M | 60.5M | 10.9M | 24.8M | - |
| Capital Expenditure | 15.6M | 48.0M | 6.26M | 63.5M | 10.3M | 12.0M | 30.8M | 69.1M | 221M | 125M | 121M |
| Free Cash Flow | 26.1M | -5.18M | 22.9M | 48.0M | 36.2M | 18.6M | 21.7M | -8.57M | -210M | -100M | -195M |
| Ratios | |||||||||||
| ROE | 2.5% | 4.8% | 2.2% | 1.5% | 2.2% | -1.1% | 2.0% | -2.6% | 4.8% | 1.0% | -3.0% |
| ROA | 1.9% | 3.8% | 1.9% | 1.3% | 1.9% | -1.0% | 1.7% | -2.0% | 3.8% | 0.8% | -2.4% |
| Net Profit Margin | 4.1% | 7.1% | 5.1% | 3.4% | 5.6% | -3.4% | 5.8% | -7.6% | 12.7% | 2.9% | -9.6% |
| Debt to Equity | 0.14x | 0.13x | 0.03x | 0.03x | 0.03x | - | 0.01x | 0.00x | 0.03x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ginwa Enterprise Group Inc dividends
- Dividend yield
- 0.90%
- Forward dividend
- -
- Payout ratio
- 86.5%
- Ex-dividend date
- Jun 20, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 13.5M | 0.04 | 86.5% |
| 2024 | CNY 3.31M | 0.01 | 4.4% |
| 2023 | CNY 3.73M | 0.01 | - |
| 2022 | CNY 909K | 0.00 | 2.7% |
| 2021 | CNY 33.6M | 0.09 | - |
| 2020 | CNY 11.2M | 0.03 | 29.7% |
| 2019 | CNY 14.9M | 0.04 | 57.6% |
| 2018 | CNY 19.4M | 0.05 | 50.6% |
| 2017 | CNY 16.7M | 0.05 | 31.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 17.458:10 on Jun 13, 2006.
Who owns Ginwa Enterprise Group Inc
- Insiders 34.30%
- Institutions 0.00%
- Public & others 65.70%
- Shares outstanding 373M
- Free float 225M
Ginwa Enterprise Group Inc company profile
- Company name
- Ginwa Enterprise Group Inc
- Ticker
- 600080.SHG
- ISIN
- CNE000000QQ8
- Exchange
- Shanghai Stock Exchange
- Listed since
- May 14, 1997
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 613
- Fiscal year end
- December
- Address
- South Building, Xi'an, China, 710075
- Phone
- 86 29 8833 6635
- Website
- ginwa.com.cn
About Ginwa Enterprise Group Inc
Ginwa Enterprise (Group) Inc. researches, develops, produces, markets, and sells traditional Chinese medicines, biological drugs, and chemical drugs primarily in China. The company offers a range of orthopaedics, immunity, children, and general medicines in various dosage forms, including tablets, capsules, powders, mixtures, oral solutions, syrups, and external solutions. It is also involved in the pharmaceutical logistics activities. The company was founded in 1996 and is headquartered in Xi'an, China.
Ginwa Enterprise Group Inc management
8- Mr. Zhuojun HanGeneral Manager · born 1965
- Mr. Boyue XingVice Chairman & Deputy GM · born 1996
- Mr. Shoufeng ZhangFinancial Director · born 1982
- Mr. Zhihua ShiDeputy General Manager · born 1976
- Ms. Xueyan ChenDeputy General Manager · born 1978
- Mr. Guang Dong ZhaoDeputy General Manager · born 1976
- Mr. Chaoyang ZhangEmployee Representative Director & Board Secretary · born 1971
- Rui HeAccounting Supervisor